Developing novel treatments for mood disorders: Accelerating discovery

Biological Psychiatry

Volumn 52, Issue 6, 2002, Pages 589-609

  Tamminga, Carol A ^a,s   Nemeroff, Charles B ^b   Blakely, Randy D ^c   Brady, Linda ^d   Carter, Cameron S ^g   Davis, Kenneth L ^h   Dingledine, Raymond ^b   Gorman, Jack M ⁱ   Grigoriadis, Dimitri E ^j   Henderson, David C ^k   Innis, Robert B ^e   Killen, John ^l   Laughren, Thomas P ^m   McDonald, William M ^b   Murphy Jr , Greer M ⁿ   Paul, Steven M ^o   Rudorfer, Matthew V ^f   Sausville, Edward ^p   Schatzberg, Alan F ⁿ   Scolnick, Edward M ^q   Suppes, Trisha ^r   more..

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Neuropharmacology and Drug Discovery and Clinical Therapeutics Programs   (United States)

^e Molecular Imaging Program   (United States)

^f NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^g UNIVERSITY OF PITTSBURGH   (United States)

^h MOUNT SINAI SCHOOL OF MEDICINE   (United States)

ⁱ NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^j NEUROCRINE BIOSCIENCES INC   (United States)

^k MASSACHUSETTS GENERAL HOSPITAL   (United States)

^l NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^m CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

ⁿ STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^o ELI LILLY AND COMPANY   (United States)

^p NATIONAL CANCER INSTITUTE   (United States)

^q MERCK RESEARCH LABORATORIES   (United States)

^r UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^s MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

more..

Author keywords

Depression bipolar disorder research resources; Government industry collaboration

Indexed keywords

AMFEBUTAMONE; AMPHETAMINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; DOPAMINE RECEPTOR STIMULATING AGENT; FLUOXETINE; FLUVOXAMINE; LAMOTRIGINE; LIOTHYRONINE; LITHIUM; METHYLPHENIDATE; MIRTAZAPINE; MODAFINIL; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; PAROXETINE; PRAMIPEXOLE; SEROTONIN 1A ANTAGONIST; SEROTONIN ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; STEROID; TACHYKININ RECEPTOR ANTAGONIST; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE;

ANIMAL BEHAVIOR; BIPOLAR DISORDER; CENTRAL NERVOUS SYSTEM; CLINICAL RESEARCH; DNA POLYMORPHISM; DNA RESPONSIVE ELEMENT; DRUG MECHANISM; DRUG RESEARCH; DRUG SCREENING; DRUG SYNTHESIS; DRUG TARGETING; DRUG UTILIZATION; FINANCIAL MANAGEMENT; GENOTYPE; HUMAN; IMAGING; IMMUNOMODULATION; MOOD DISORDER; NEUROLOGIC EXAMINATION; NEUROMODULATION; NEUROPROTECTION; PHARMACOGENETICS; PHENOTYPE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHIATRIC TREATMENT; REVIEW; SECOND MESSENGER; TRANSCRANIAL MAGNETIC STIMULATION; VAGUS NERVE STIMULATION;

ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIORAL RESEARCH; BRAIN; CLINICAL TRIALS; DIAGNOSTIC IMAGING; FINANCING, GOVERNMENT; GENETICS, BEHAVIORAL; HUMANS; MOOD DISORDERS; NATIONAL INSTITUTE OF MENTAL HEALTH (U.S.); PHARMACOGENETICS; RESEARCH; UNITED STATES;

EID: 0037106951     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(02)01470-1     Document Type: Review

References (83)

1. Abrams R., Taylor M.A. Diencephalic stimulation and the effects of ECT in endogenous depression. Br J Psychiatry. 129:1976;482-485.
2. Allen P.B., Ouimet C.C., Greengard P. Spinophilin, a novel protein phosphatase 1 binding protein localized to dendritic spines. Proc Natl Acad Sci USA. 94:1997;9956-9961.
3. Altshuler L.L., Post R.M., Leverich G.S., Mikalauskas K., Rosoff A., Ackerman L. Antidepressant-induced mania and cycle acceleration A controversy revisited. Am J Psychiatry. 152:1995;1130-1138.
4. Anderson I.M. Selective serotonin reuptake inhibitors versus tricyclic antidepressants A meta-analysis of efficacy and tolerability. J Affect Disord. 58:2000;19-36.
5. Andrews J.M., Ninan P.T., Nemeroff C.B. Venlafaxine A novel antidepressant that has a dual mechanism of action. Depression. 4:1996;48-56.
6. Bailine S.H., Rifkin A., Kayne E., Selzer J.A., Vital-Herne J., Blieka M., et al. Comparison of bifrontal and bitemporal ECT for major depression. Am J Psychiatry. 157:2000;121-123.
7. Bauman A.L., Apparsundaram S., Ramamoorthy S., Wadzinski B.E., Vaughan R.A., Blakely R.D. Cocaine and antidepressant-sensitive biogenic amine transporters exist in regulated complexes with protein phosphatase 2A. J Neurosci. 20:2000;7571-7578.
8. Bejjani B.P., Damier P., Arnulf I., Thivard L., Bonnet A.M., Dormont D., et al. Transient acute depression induced by high-frequency deep-brain stimulation. N Engl J Med. 340:1999;1476-1480.
9. Belanoff J.K., Flores B.H., Kalezhan M., Sund B., Schatzberg A.F. Rapid reversal of psychotic depression using mifepristone. J Clin Psychopharmacol. 21:2001;516-521.
10. Black D.W., Hulbert J., Nasrallah A. The effect of somatic treatment and comorbidity on immediate outcome in manic patients. Compr Psychiatry. 30:1989;74-79.
11. Blakely R.D., Ramamoorthy S., Schroeter S., Qian Y., Apparsundaram S., Galli A., et al. Regulated phosphorylation and trafficking of antidepressant-sensitive serotonin transporter proteins. Biol Psychiatry. 44:1998;169-178.
12. Blier P., Bergeron R. The use of pindolol to potentiate antidepressant medication J. Clin. Psychiatry. 59:(suppl 5):1998;16-23.
13. Calabrese J.R., Bowden C.L., Sachs G.S., Ascher J.A., Monaghan E., Rudd G.D. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry. 60:1999;79-88.
14. Cappiello A., McDougle C.J., Malison R.T., Heninger G.R., Price L.H. Yohimbine augmentation of fluvoxamine in refractory depression A single-blind study. Biol Psychiatry. 38:1995;765-767.
15. Charney D.S., Berman R.M., Miller H.L. Treatment of depression. Schatzberg A.F., Nemeroff C.B., Textbook of Psychopharmacology. 1998;705-731 American Psychiatric Press, Washington, DC.
16. Cravchik A, Goldman D (2000): Neurochemical individuality: Genetic diversity among human dopamine and serotonin receptors and transporters. Arch Gen Psychiatry 57:1105-1114.
17. Davidson JT, Nemeroff CB, the Hypericum Depression Trial Study Group (in press): An extract of hypericum perforatum (St. John's Wort) in major depressive disorder: A randomized, double-blind trial with placebo and active control. JAMA.
18. de Boer T. The pharmacologic profile of mirtazapine. J Clin Psychiatry. 57:(suppl 4):1996;19-25.
19. Drevets W.C. Neuroimaging studies of mood disorders. Biol Psychiatry. 48:2000;813-829.
20. Drysdale CM, McGraw DW, Stack CB, Stephens JC, Judson RS, Nandabalan K, et al (2000): Complex promoter and coding region beta 2-adrenergic receptor haplotypes after receptor expression and predict in vivo responsiveness. Proc Natl Acad Sci USA 97:10483-10488.
21. Duman R.S., Heninger G.R., Nestler E.J. A molecular and cellular theory of depression. Arch Gen Psychiatry. 54:1997;597-606.
22. Ernst E., Rand J.I., Stevinson C. Complementary therapies for depression An overview. Arch Gen Psychiatry. 55:1998;1026-1032.
23. Fan JB, Chen X, Halushka MK (2000): Parallel genotyping of human SNPs using generic high-density oligonucleotide tag arrays [in Process Citation]. Genome Res 10:853-860.
24. Fava M., Davidson K.G. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am. 19:1996;179-200.
25. Ferguson J.M., Shrivastava R.K., Stahl S.M., Hartford J.T., Borian F., Ieni J., et al. Reemergence of sexual dysfunction in patients with major depressive disorder Double-blind comparison of nefazodone and sertraline. J Clin Psychiatry. 62:2001;24-29.
26. Fink M., Ottosson J.O. A theory of convulsive therapy in endogenous depression Significance of hypothalamic functions. Psychiatry Res. 2:1980;49-61.
27. Fujita M., Charney D.S., Innis R.B. Imaging serotonergic neurotransmission in depression Hippocampal pathophysiology may mirror global brain alterations. Biol Psychiatry. 48:2000;801-812.
28. Gelenberg A.J., Laukes C., McGahuey C., Okayli G., Moreno F., Zentner L., et al. Mirtazapine substitution in SSRI-induced sexual dysfunction. J Clin Psychiatry. 61:2000;356-360.
29. Haria M., Fitton A., McTavish D. Trazodone. A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders. Drugs Aging. 4:1994;331-355.
30. Heim C., Nemeroff C.B. The impact of early adverse experiences on brain systems involved in the pathophysiology of anxiety and affective disorders. Biol Psychiatry. 46:1999;1509-1522.
31. Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology. 23:2000;477-501.
32. Hyman S.E., Nestler E.J. Initiation and adaptation A paradigm for understanding psychotropic drug action. Am J Psychiatry. 153:1996;151-162.
33. Innis R, Ferguson S, Brady L, Esmond R, Frank R (2001, July): Positron-emission tomography tracers as intellectual property. J Clin Pharmacol(suppl):107S.
34. Jain KK (2000): Applications of biochip and microarray systems in pharmacogenomics. Pharmacogenomics 1:289-307.
35. Judson R, Stephens J, Windemuth A (2000): The predictive power of haplotypes in clinical response. Pharmacogenomics 1:15-26.
36. Kalin N.H. Management of the depressive component of bipolar disorder. Depress Anxiety. 4:1996;190-198.
37. Kasper S., el Giamal N., Hilger E. Reboxetine The first selective noradrenaline re-uptake inhibitor. Expert Opin Pharmacother. 1:2000;771-782.
38. Kim DK, Lim SW, Lee S, Sohn SE, Kim S, Haln CG, et al (2000): Serotonin transporter gene polymorphism and antidepressant response. Neuroreport 11:215-219.
39. Kramer M.S., Cutler N., Feighner J., Shrivastava R., Carman J., Sramek J.J., et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science. 281:1998;1640-1645.
40. Krystal A.D., Weiner R.D. ECT seizure therapeutic adequacy. Convuls Ther. 10:1994;153-164.
41. Lawson J.S., Inglis J., Delva N.J., Rodenburg M., Waldron J.J., Letemendia F.J. Electrode placement in ECT Cognitive effects. Psychol Med. 20:1990;335-344.
42. Letemendia F.J., Delva N.J., Rodenburg M., Lawson J.S., Inglis J., Waldron J.J., et al. Therapeutic advantage of bifrontal electrode placement in ECT. Psychol Med. 23:1993;349-360.
43. Mathew SJ, Coplan JD, Smith ELP, Schoepp DD, Rosenblum LA, Gorman JM (in press): Glutamate-HPA axis interactions: Implications for mood and anxiety disorders. CNS Spectrums.
44. McGrath P.J., Stewart J.W., Nunes E.V., Ocepek-Welikson K., Rabkin J.G., Quitkin F.M., et al. A double-blind crossover trial of imipramine and phenelzine for outpatients with treatment-refractory depression. Am J Psychiatry. 150:1993;118-123.
45. Mukherjee S., Debsikdar V. Absence of neuroleptic-induced parkinsonism in psychotic patients receiving adjunctive electroconvulsive therapy. Convuls Ther. 10:1994;53-58.
46. Mundo E, Walker M, Cate T, Macciardi F, Kennedy JL (2001): The role of serotonin transporter protein gene in antidepressant-induced mania in bipolar disorder: Preliminary findings. Arch Gen Psychiatry 58:539-544.
47. Murphy G.M. Jr, Pollock B.G., Kirshner M.A., Pascoe N., Cheuk W., Mulsant B.H., et al. CYP2D6 genotyping with oligonucleotide microarrays and nortriptyline concentrations in geriatric depression. Neuropsychopharmacology. 25:2001;737-743.
48. Musselman D.L., Miller A.H., Porter M.R., Manatunga A., Gao F., Penna S., et al. Higher than normal plasma interleukin-6 concentrations in cancer patients with depression Preliminary findings. Am J Psychiatry. 158:2001;1252-1257.
49. Nemeroff C.B. Augmentation strategies in patients with refractory depression. Depress Anxiety. 4:1996;169-181.
50. Nemeroff CB (in press): Treating depression in the bipolar patient. J Clin Psychiatry.
51. Nobler M.S., Sackeim H.A., Prohovnik I., Moeller J.R., Mukherjee S., Schnur D.B., et al. Regional cerebral blood flow in mood disorders, III. Treatment and clinical response. Arch Gen Psychiatry. 51:1994;884-897.
52. Owens M.J., Ieni J.R., Knight D.L., Winders K., Nemeroff C.B. The serotonergic antidepressant nefazodone inhibits the serotonin transporter In vivo and ex vivo studies. Life Sci. 57:1995;L373-L380.
53. Owens M.J., Knight D.L., Nemeroff C.B. Paroxetine binding to the rat norepinephrine transporter in vivo. Biol Psychiatry. 47:2000;842-845.
54. Pfost DR, Boyce-Jacino MT, Grant DM (2000): A SNPshot: Pharmacogenetics and the future of drug therapy [In Progress Citation]. Trends Biotechnol 18:334-338.
55. Pollock BG, Ferrell RE, Mulsant BH, Mazumdar S, Miller M, Sweet RA, et al (2000): Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 23:587-590.
56. Potter W.Z., Manji H.K., Rudorfer M.V. Tricyclics and tetracyclics. Schatzberg A.F., Nemeroff C.B., Textbook of Psychopharmacology. 1998;199-218 American Psychiatric Press, Washington, DC.
57. Prudic J., Haskett R.F., Mulsant B., Malone K.M., Pettinati H.M., Stephens S., et al. Resistance to antidepressant medications and short-term clinical response to ECT. Am J Psychiatry. 153:1996;985-992.
58. Ramamoorthy S., Blakely R.D. Phosphorylation and sequestration of serotonin transporters differentially modulated by psychostimulants. Science. 285:1999;763-766.
59. Robertson JA (2001): Consent and privacy in pharmacogenetic testing. Nat Genet 28:207-209.
60. Rosen R.C., Lane R.M., Menza M. Effects of SSRIs on sexual function A critical review. J Clin Psychopharmacol. 19:1999;67-85.
61. Roses AD (2000): Pharmacogenetics and the practice of medicine. Nature 405:857-865.
62. Rudorfer M.V. Unilateral ECT Medications and monitoring. Am J Psychiatry. 146:1989;285-286.
63. Sachs G.S., Lafer B., Stoll A.L., Banov M., Thibault A.B., Tohen M., et al. A double-blind trial of bupropion versus desipramine for bipolar depression. J Clin Psychiatry. 55:1994;391-393.
64. Sackeim H.A. The anticonvulsant hypothesis of the mechanisms of action of ECT Current status. J ECT. 15:1999;5-26.
65. Sackeim H.A., Decina P., Prohovnik I., Portnoy S., Kanzler M., Malitz S. Dosage, seizure threshold, and the antidepressant efficacy of electroconvulsive therapy. Ann N Y Acad Sci. 462:1986;398-410.
66. Sackeim H.A., Long J., Luber B., Moeller J.R., Prohovnik I., Devanand D.P., et al. Physical properties and quantification of the ECT stimulus I. Basic principles. Convuls Ther. 10:1994;93-123.
67. Salzman C. ECT, research, and professional ambivalence. Am J Psychiatry. 155:1998;1-2.
68. Sanders A.R., Detera-Wadleigh S.D. Molecular genetics of mood disorders. Charney D.S., Nestler E.J., Bunney B.S., Neurobiology of Mental Illness. 1999;299-316 Oxford University Press, New York.
69. Schatzberg A.F., Rothschild A.J., Langlais P.J., Bird E.D., Cole J.O. A corticosteroid/dopamine hypothesis for psychotic depression and related states. J Psychiatr Res. 19:1985;57-64.
70. Sharma A., Goldberg M.J., Cerimele B.J. Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor. J Clin Pharmacol. 40:2000;161-167.
71. Shelton R.C., Keller M.B., Gelenberg A., Dunner D.L., Hirschfeld R., Thase M.E., et al. Effectiveness of St John's wort in major depression A randomized controlled trial. JAMA. 285:2001;1978-1986.
72. Smeraldi E, Zanardi R, Benedetti F, Di Bella D, Perez J, Catalano M (1998): Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine [see comments]. Mol Psychiatry 3:508-511.
73. Smith W.T., Londborg P.D., Glaudin V., Painter J.R. Short-term augmentation of fluoxetine with clonazepam in the treatment of depression A double-blind study. Am J Psychiatry. 155:1998;1339-1345.
74. Stewart J.W., Tricamo E., McGrath P.J., Quitkin F.M. Prophylactic efficacy of phenelzine and imipramine in chronic atypical depression Likelihood of recurrence on discontinuation after 6 months' remission. Am J Psychiatry. 154:1997;31-36.
75. Stout S.C., Owens M.J., Nemeroff C.B. Neurokinin(1) receptor antagonists as potential antidepressants. Annu Rev Pharmacol Toxicol. 41:2001;877-906.
76. Swartz C.M. Asymmetric bilateral right frontotemporal left frontal stimulus electrode placement for electroconvulsive therapy. Neuropsychobiology. 29:1994;174-178.
77. Tatsumi M., Groshan K., Blakely R.D., Richelson E. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 340:1997;249-258.
78. Thase M.E., Entsuah A.R., Rudolph R.L. Remission ratesduring treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry. 178:2001;234-241.
79. Tortella F.C., Long J.B. Endogenous anticonvulsant substance in rat cerebrospinal fluid after a generalized seizure. Science. 228:1985;1106-1108.
80. Vetulani J., Nalepa I. Antidepressants Past, present and future. Eur J Pharmacol. 405:2000;351-363.
81. Yudofsky S.C. Parkinson's disease, depression, and elec-trical stimulation of the brain. N Engl J Med. 340:1999;1500-1502.
82. Zanardi R, Benedetti F, DiBella D, Catalano M, Smeraldi E (2000): Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene [letter]. J Clin Psychopharmacol 20:105-107.
83. Zobel A.W., Nickel T., Kunzel H.E., Ackl N., Sonntag A., Ising M., et al. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression The first 20 patients treated. J Psychiatr Res. 34:2000;171-181.